Kolexia
Robert Caroline Dermatologie
Robert Caroline
Dermatologie
Gustave-Roussy
Villejuif, France
977 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Mélanome Tumeurs cutanées Métastase tumorale Carcinomes Tumeurs du cerveau Récidive tumorale locale Tumeurs du poumon Maladies de la peau Carcinome épidermoïde

Collaborateurs

Voir plus
Grob Jean-Jacques
Grob Jean-Jacques
Hôpital La Timone, Marseille, France
Lebbe Celeste
Lebbe Celeste
Hôpital Saint-Louis, Paris, France
Mateus Christine
Mateus Christine
Gustave-Roussy, Villejuif, France
Mortier Laurent
Mortier Laurent
Hôpital Huriez, Lille, France

Industries

Voir plus
MSD
38 collaboration(s)
Dernière en 2023
Sanofi
36 collaboration(s)
Dernière en 2023
Pierre Fabre
36 collaboration(s)
Dernière en 2023
BMS
36 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma: A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Essai Clinique (Roche)   21 mars 2024
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587): A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Essai Clinique (Merck & Co.)   20 mars 2024
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA
Essai Clinique (Pfizer)   17 mars 2024
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors: Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors
Essai Clinique (IO Biotech)   15 mars 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   07 mars 2024
RELATIVITY-127: A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Essai Clinique (BMS)   29 février 2024
Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitors.
Clinics and research in hepatology and gastroenterology   29 février 2024
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200): A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Essai Clinique (Emd Serono)   14 février 2024
A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors: A Phase 1 Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Essai Clinique (Seagen)   09 février 2024
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).: A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)
Essai Clinique (Anaveon AG)   09 février 2024